Navigation Links
Ambry Genetics to Develop Custom Assays Targeted to Patients with Hereditary Ovarian Cancer
Date:3/25/2019

Ambry Genetics, a Konica Minolta Company (Ambry), and leading provider of clinical and research genetic testing, today announced a new laboratory services agreement with Clovis Oncology Inc., a biopharmaceutical company which shares Ambry’s commitment to advancing precision medicine for cancer. Through this laboratory services agreement, Ambry Genetics and Clovis Oncology seek to identify clinical trial patients who may benefit from Rubraca®, a therapy currently approved in the U.S. and Europe in multiple advanced ovarian cancer settings.

Approximately 10 to 15% of ovarian cancer diagnoses are based on hereditary mutations of BRCA, meaning they are directly linked to mutations in the BRCA1 or BRCA2 genes passed on from a parent. Ambry’s genetic tests can identify mutations in these two genes, as well as related genes involved in the DNA repair pathway, thus enabling identification of potential risk, earlier diagnosis and more precise treatment.

"We are very excited to be working with the Clovis team, which is aligned with our precision medicine initiatives,” said Brigette Tippin Davis, Ph.D., FACMG, Senior Vice President of Research & Development of Ambry Genetics, Inc. “Our mission is to help identify patients eligible for optimal therapies to improve outcomes and enhance quality of life.”

Clovis chose to perform retrospective BRCA testing with Ambry Genetics, a high-quality genetics lab positioned to become a key player in the precision medicine space.

About Ambry Genetics
Ambry Genetics is a leader in clinical diagnostic and software solutions, combining both to offer comprehensive and high quality genetic testing. As part of the Konica Minolta family, Ambry Genetics is responsibly applying new technologies to the molecular diagnostics market to bring about precision medicine. Founded in 1999, Ambry Genetics has longstanding expertise in clinical genetic testing. For more information about Ambry Genetics, visit ambrygen.com.

Press Contact:
Jackie Copp
press(at)ambrygen(dot)com
480-606-8180

Read the full story at https://www.prweb.com/releases/ambry_genetics_to_develop_custom_assays_targeted_to_patients_with_hereditary_ovarian_cancer/prweb16160917.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology news :

1. Ambry Genetics Presents Research on the Importance of Reclassifying Disease-Causing Genes at the National Society of Genetic Counselors (NSGC) Annual Meeting
2. Diagenode Announces Acquisition of Service Provider NXT-Dx to Complement Epigenetics Assay Services
3. ACMG Annual Clinical Genetics Meeting Named One of the Fastest Growing Meetings in USA for Fourth Time
4. American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect
5. Seven researchers awarded for work presented at yeast genetics conference
6. ASHG and NHGRI award genetics and public policy fellowship
7. ASHG and NHGRI award first genetics and education fellowship
8. MARC travel awards announced for: American Society of Human Genetics 2014 Annual Meeting
9. MARC travel awards announced for GSA: Mouse Molecular Genetics Conference
10. American Society of Human Genetics 2014 Annual Meeting
11. Behind the scenes of genetics, leukemia in Down syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/4/2019)... ... April 02, 2019 , ... Researchers from Ambry Genetics ... RNA genetic testing (RGT), as a supplement to DNA genetic testing, improves variant ... poster, is one of 13 presentations at the 2019 American College of Medical ...
(Date:4/1/2019)... ... April 01, 2019 , ... ... Characterizing Skin Related Conditions” by the US Patent and Trademark Office on January ... an invention by uBiome collaborators Dr. Zachary Apte, Dr. Daniel Almonacid, Dr. ...
(Date:3/29/2019)... ... ... In the development of biosimilars, the broad definition of the similarity concept in ... several manufacturers have been successful and numerous follow-on biologics are approved in the US ... analytical similarity is achieved in biosimilars based on recently approved products in the US. ...
Breaking Biology News(10 mins):
(Date:3/19/2019)... ... March 19, 2019 , ... Cirrascale Cloud ... it has begun offering NVIDIA® DGX-1™ deep learning systems as part of its ... provide the highest performance for artificial intelligence and deep learning research and development. ...
(Date:3/14/2019)... OKLAHOMA CITY (PRWEB) , ... March 14, 2019 ... ... AAALAC International for their facility in Oklahoma City, OK. EyeCRO joins the Department ... University of Oklahoma Health Sciences Center as the fifth institution in Oklahoma to ...
(Date:3/14/2019)... ... March 14, 2019 , ... ON ... its Canadian partner, the Eye Machine Canada Inc., had been given approval to ... for treating Age-Related Macular Degeneration (AMD). , The previous month, the medical devices ...
(Date:3/14/2019)... ... March 14, 2019 , ... ... gold standard solution for preclinical research organizations. It is a low code, ... connected systems and facilities, innovative technology-driven automated data capture and seamless data ...
Breaking Biology Technology: